Systematic review / meta-analysis / 2013
Zinc intake significantly reduced the duration of common cold symptoms and cold incidence, but increased adverse events such as bad taste and nausea.
A systematic review and meta-analysis assessed randomized, double-blind, placebo-controlled trials examining zinc for cold treatment or prevention. Zinc was associated with a significant reduction in cold duration (MD -1.03 days, 95% CI -1.72 to -0.34; P = 0.003) and cold incidence (IRR 0.64, 95% CI 0.47 to 0.88; P = 0.006), but not symptom severity (MD -1.06, 95% CI -2.36 to 0.23; P = 0.11). Overall adverse events (OR 1.58, 95% CI 1.19 to 2.09), bad taste (OR 2.31, 95% CI 1.71 to 3.11), and nausea (OR 2.15, 95% CI 1.44 to 3.23) were significantly higher in the zinc group. The authors noted that very high heterogeneity indicates averaged estimates must be viewed with caution.
- Study type
- Systematic review and meta-analysis of randomized controlled trials
- Who was studied
- 1,387 participants in 16 therapeutic trials and 394 participants in 2 preventive trials
- What was measured
- Duration, severity, and incidence of common cold symptoms; adverse events
THE PAPER
Zinc for the common cold.
Singh M, Das RR. Cochrane Database Syst Rev, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.